WCLC: MSD/Daiichi build case for phase 3 ADC for lung cancer
MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-st